In earlier reports, we described the beneficial effects of Oxy210, a dual inhibitor of Hh and TGF-β signaling, on profibrotic responses observed in HSCs in vitro, and on the progression of liver fibrosis in vivo, using a humanized mouse model of NASH [22]. The gene discussed is TGFB1; the disease is Hepatic fibrosis.